0001799191-23-000029.txt : 20230809 0001799191-23-000029.hdr.sgml : 20230809 20230808183506 ACCESSION NUMBER: 0001799191-23-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncology Institute, Inc. CENTRAL INDEX KEY: 0001799191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39248 FILM NUMBER: 231152889 BUSINESS ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 BUSINESS PHONE: 562-735-3226 MAIL ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 FORMER COMPANY: FORMER CONFORMED NAME: DFP HEALTHCARE ACQUISITIONS CORP. DATE OF NAME CHANGE: 20200108 8-K 1 toi-20230808.htm 8-K toi-20230808
0001799191false00017991912023-08-082023-08-080001799191us-gaap:CommonStockMember2023-08-082023-08-080001799191us-gaap:WarrantMember2023-08-082023-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

August 8, 2023
Date of Report (date of earliest event reported)
__________________________________________________________
The Oncology Institute, Inc.
(Exact name of registrant as specified in its charter)
__________________________________________________________
Delaware
(State or other jurisdiction of
incorporation or organization)
001-39248
(Commission File Number)
84-3562323
(I.R.S. Employer Identification Number)
18000 Studebaker Rd, Suite 800
Cerritos, California 90703
(Address of principal executive offices and zip code)
(562) 735-3226
(Registrant's telephone number, including area code)
__________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.0001TOIThe Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
TOIIW
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company    ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02. Results of Operations and Financial Condition

On August 8, 2023, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2023 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein.

The information contained in Item 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:

Exhibit No.Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
        


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 8, 2023

The Oncology Institute, Inc.
By:
/s/ Mihir Shah
Name:
Mihir Shah
Title:
Chief Financial Officer

 EX-99.1 2 item991-q22023earningsrele.htm EX-99.1 Document

image_0.jpg

FOR IMMEDIATE RELEASE

The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
CERRITOS, Calif., August 8, 2023 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2023 and reaffirmed its full year 2023 guidance.

Recent Operational Highlights:
•Completed the acquisition of Southland Radiation Oncology Network (“SRON”)
•Signed a new partnership with Massive Bio to further enhance randomization of trials
•Increased patient visits 14% compared to the prior year quarter
•Increased oral drugs dispensed 38% compared to the prior year quarter

Second Quarter 2023 Financial Highlights
•Consolidated revenue of $80 million, an increase of 32% compared to the prior year quarter
•Gross profit of $15 million, an increase of 36% compared to the prior year quarter, and gross margin of 18.8%, an increase from 18.3% the prior year quarter
•Net loss of $16.9 million compared to net loss of $5.5 million for the prior year quarter
•Basic and diluted (loss) earnings per share of $(0.19) and $(0.19), respectively, compared to $(0.06) and $(0.06), respectively, for the prior year quarter
•Adjusted EBITDA of $(6.9) million compared to $(6.9) million for the prior year quarter
•Cash, cash equivalents, and investments of $98 million as of June 30, 2023
Management Commentary
Daniel Virnich, CEO of TOI, commented, "I am very pleased with our strong performance in the second quarter of 2023, as we delivered 32% topline growth and expanded our gross margin. Fee-for-service and oral drug revenue performed better than we expected and organic growth was robust in both established and expansion markets. We formed two new strategic partnerships during the quarter and acquired SRON to expand our presence in the Greater Los Angeles market. As we look toward the balance of the year, we are reaffirming our 2023 guidance given the momentum in our business and our optimism that we can execute against our strategic initiatives. Longer term, we are confident in our ability to achieve sustainable growth and deliver even greater value to our patients, partners and other key stakeholders.”

Reaffirmed Outlook for Fiscal Year 2023
TOI uses Adjusted EBITDA, a non-GAAP metric, as an additional tool to assess its operational performance. See "Financial Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception for forward-looking information provided under Regulation S-K, TOI is not reasonably able to provide a quantitative reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure, without unreasonable efforts due to uncertainties regarding taxes, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized (gains) losses on investments, practice acquisition-related costs, consulting and legal fees, transaction costs and other non-cash items. The variability of these items could have an unpredictable, and potentially significant, impact on TOI’s future GAAP financial results. TOI expects interest expense in the range of $4 million to $5


million, other adjustment add backs in the range of $2 million to $4 million, and depreciation and amortization in the range of $4 million to $6 million. TOI is not adding back new clinic startup or acquisition costs for this non-GAAP metric.
2023 Guidance - Reaffirmed
Revenue$290 to $320 million, representing approximately 15% to 27% growth over 2022 revenue
Gross Profit$60 to $70 million
Adjusted EBITDA$(25) to $(28) million
Value-based lives(1)
1.75 million to 2.0 million lives
(1)     Represents lives under capitation contracts.

TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings during 2023. TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.
Second Quarter 2023 Results (for the three months ended June 30, 2023)

Consolidated revenue for Q2 2023 was $80 million, an increase of 31.7% compared to Q2 2022, and a 5.3% increase compared to Q1 2023.
Revenue for patient services was $53 million, up 36.6% compared to Q2 2022. Growth in patient services revenue was driven by an increase in fee-for-service ("FFS") revenue due to practice acquisitions and an overall increase in clinic count. Dispensary revenue increased 24.6% compared to Q2 2022 due to an increase in the number of filled prescriptions, offset by a slight decrease in the average revenue per filled prescription. Clinical trials & other revenue increased by 0.5% compared to Q2 2022 primarily due to an increase in California Proposition 56 revenue and TOI Clinical Research revenue.
Gross profit in Q2 2023 was $15 million, an increase of 35.7% compared to Q2 2022. The increase was primarily driven by improved cost management of oral and IV drugs and enhanced rebate opportunities. Gross profit is calculated by subtracting direct costs of patient services, dispensary, and clinical trials and other from consolidated revenues.
Selling, general and administrative ("SG&A") expenses in Q2 2023 were $29 million or 35.8% of revenue, compared with $28 million, or 46.5% of revenue, in Q2 2022. During Q2 2023, share-based compensation expense was $4 million. The remainder of the increase in SG&A expenses was due to headcount and other costs associated with operating as a public company and supporting revenue growth and expansion into new markets.
Net loss for Q2 2023 was $16.9 million, an increase of $11 million in net loss compared to Q2 2022 primarily due to a $10.8 million decrease in the change in fair value of earnout liabilities. Adjusted EBITDA was $(6.9) million in Q2 2023 and Q2 2022.
First Half 2023 Results (for the six months ended June 30, 2023)
Consolidated revenue for the first half of 2023 was $156 million, an increase of 34.7% compared to the first half of 2022.
Revenue for patient services the first half of 2023 was $104 million, up 39.8% compared to the first half of 2022. Growth in patient services revenue was driven by an increase in FFS revenue due to practice acquisitions and an overall increase in clinic count. Dispensary revenue increased 27.1% compared to the first half of 2022 due to an increase in the number of filled prescriptions, offset by a slight decrease in the average revenue per filled prescription. Clinical trials & other revenue increased by 8.7% compared to the first half of 2022 primarily due to an increase in California Proposition 56 revenue and TOI Clinical Research revenue.

Gross profit in the first half of 2023 was $29 million, an increase of 24.5% compared to the first half of 2022. The increase was primarily driven by improved cost management of oral and IV drugs and enhanced rebate opportunities. Gross profit is calculated by subtracting direct costs of patient services, dispensary, and clinical trials and other from consolidated revenues.



SG&A expenses in the first half of 2023 were $58 million or 36.8% of revenue, compared with $58 million, or 50.1% of revenue, in the first half of 2022. During the first half of 2023, share-based compensation expense was $9 million compared to $15 million for the same period of 2022.

Net loss for the first half of 2023 was $47 million, a decrease of $61 million in income compared to the first half of 2022 primarily due to a $46 million decrease in the change in fair value of earnout liabilities, as well as a goodwill impairment charge of $17 million in the first half of 2023 that did not occur in the same period of 2022. Adjusted EBITDA was $(14) million, a decrease of $2 million compared to the first half of 2022.

Webcast and Conference Call
TOI will host a conference call and webcast on Tuesday, August 8, 2023 at 5:00 p.m. (Eastern Time) to discuss second quarter results.

The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13739395. The replay will be available until August 15, 2023.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of TOI's website at https://investors.theoncologyinstitute.com.
About The Oncology Institute, Inc.
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 700 teammates in over 67 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “preliminary,” “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “predict,” “potential,” “guidance,” “approximately,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of TOI and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of TOI. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2023 outlook discussed herein, the outcome of judicial and administrative proceedings to which TOI may become a party or governmental investigations to which TOI may become subject that could interrupt or limit TOI’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOI’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet, or to cure any deficiency with respect to, stock exchange listing standards; the impact of COVID-19 on TOI’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC, including the Item 1A. "Risk Factors" section of TOI's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 16, 2023 and any subsequent Current Reports on Form 8-K. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI does not presently know or that TOI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect TOI’s plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOI’s assessments to change. TOI does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOI’s


assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Financial Information; Non-GAAP Financial Measures
Some of the financial information and data contained in this press release, such as Adjusted EBITDA, have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). TOI believes that the use of Adjusted EBITDA provides an additional tool to assess operational performance and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. TOI’s non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in TOI's financial statements. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with TOI’s financial statements and the related notes thereto.
TOI defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, net interest expense, income taxes, non-cash addbacks, share-based compensation, goodwill impairment charges, changes in fair value of liabilities, unrealized gains or losses on investments and other adjustments to add-back the following: consulting and legal fees related to acquisitions, deferred consideration payment for practice acquisition, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temporary labor and recruiting charges to build out our corporate infrastructure. A reconciliation of Adjusted EBITDA to net (loss) income, the most comparable GAAP metric, is set forth below.
Adjusted EBITDA Reconciliation
Three Months Ended June 30,Change
(dollars in thousands)20232022$%
Net (loss) income$(16,897)$(5,453)$(11,444)209.9 %
Depreciation and amortization1,329 1,098 231 21.0 %
Interest expense, net1,638 61 1,577 2,585.2 %
Income tax expense (benefit)99 (32)131 (409.4)%
Non-cash addbacks(1)
24 108 (84)(77.8)%
Share-based compensation4,107 6,514 (2,407)(37.0)%
Changes in fair value of liabilities(135)(12,865)12,730 (99.0)%
Unrealized (gains) losses on investments267 — 267 N/A
Practice acquisition-related costs(2)
55 111 (56)(50.5)%
Post-combination compensation expense(3)
581 — 581 N/A
Consulting and legal fees(4)
929 1,144 (215)(18.8)%
Infrastructure and workforce costs(5)
1,042 1,634 (592)(36.2)%
Transaction costs(6)
20 750 (730)(97.3)%
Adjusted EBITDA$(6,941)$(6,930)$(11)0.2 %
(1)    During the three months ended June 30, 2023, non-cash addbacks were primarily comprised of non-cash rent of $27 and net reversal of bad debt recovery of $2. During the three months ended June 30, 2022, non-cash addbacks were primarily comprised of reversals of bad debt recoveries of $105 and non-cash rent of $3.
(2)    Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.
(3)    Deferred consideration payments for practice acquisitions that are contingent upon the seller’s future employment at the Company.
(4)    Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees, and related to certain advisory projects during the three months ended June 30, 2023. During the three months ended June 30, 2022, these fees related to advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.


(5)    Infrastructure and workforce costs were comprised of recruiting expenses to build out corporate infrastructure of $430 and $1,207, software implementation fees of $22 and $31, severance expenses resulting from cost rationalization programs of $250 and $67, and temporary labor of $339 and $329 during the three months ended June 30, 2023 and 2022, respectively.
(6)    Transaction costs incurred during the three months ended June 30, 2022 were comprised of consulting, legal, administrative and regulatory fees associated with the Business Combination.
Six Months Ended June 30,Change
(dollars in thousands)20232022$%
Net (loss) income$(46,895)$13,833 $(60,728)(439.0)%
Depreciation and amortization2,598 2,085 513 24.6 %
Interest expense, net3,081 135 2,946 2,182.2 %
Income tax expense (benefit)143 148 (5)(3.4)%
Non-cash addbacks(1)165 305 (140)(45.9)%
Share-based compensation9,072 15,067 (5,995)(39.8)%
Goodwill impairment charges16,867 — 16,867 N/A
Changes in fair value of liabilities(4,348)(50,844)46,496 (91.4)%
Unrealized (gains) losses on investments124 — 124 N/A
Practice acquisition-related costs(2)71 533 (462)(86.7)%
Post-combination compensation expense(3)1,163 — 1,163 N/A
Consulting and legal fees(4)1,514 1,799 (285)(15.8)%
Infrastructure and workforce costs(5)2,116 2,587 (471)(18.2)%
Transaction costs(6)28 2,194 (2,166)(98.7)%
Adjusted EBITDA$(14,301)$(12,158)$(2,143)17.6 %
(1)    During the six months ended June 30, 2023, non-cash addbacks were primarily comprised of non-cash rent of $167 and net reversal of bad debt recovery of $1. During the six months ended June 30, 2022, non-cash addbacks were primarily comprised of net credit losses of $259 and non-cash rent of $32.
(2)    Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.
(3)    Deferred consideration payments for practice acquisitions that are contingent upon the seller’s future employment at the Company.
(4)    Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees, and related to certain advisory projects during the six months ended June 30, 2023. During the six months ended June 30, 2022, these fees related to advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.
(5)    Infrastructure and workforce costs were comprised of recruiting expenses to build out corporate infrastructure of $892 and $1,631, software implementation fees of $52 and $57, severance expenses resulting from cost rationalization programs of $265 and $85, and temporary labor of $907 and $814 during the six months ended June 30, 2023 and 2022, respectively.
(6)    Transaction costs incurred during the six months ended June 30, 2022 were comprised of consulting, legal, administrative and regulatory fees associated with the Business Combination.
Key Business Metrics
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Clinics (1)
81 69 81 69 
Markets15 13 15 13 
Lives under value-based contracts (millions)1.8 1.7 1.8 1.7 
Net (loss) income $(16,897)$(5,453)$(46,895)$13,833 
Adjusted EBITDA (in thousands)$(6,941)$(6,930)$(14,301)$(12,158)
(1)    Includes independent oncology practices to which we provide limited management services, but do not bear the operating costs.


Consolidated Balance Sheets (Unaudited)
(in thousands except share data)
June 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$28,892 $14,010 
Marketable securities10,291 59,796 
Accounts receivable, net46,394 39,816 
Other receivables499 617 
Inventories, net12,168 9,261 
Prepaid expenses5,827 6,918 
Total current assets104,071 130,418 
Non-current investments58,944 58,354 
Property and equipment, net10,772 8,547 
Operating right of use assets29,041 24,494 
Intangible assets, net19,344 17,957 
Goodwill7,230 21,418 
Other assets557 477 
Total assets$229,959 $261,665 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$13,123 $9,372 
Current portion of operating lease liabilities6,001 5,498 
Income taxes payable256 255 
Accrued expenses and other current liabilities14,126 14,595 
Total current liabilities33,506 29,720 
Operating lease liabilities26,647 22,060 
Derivative warrant liabilities89 350 
Derivative earnout liabilities34 803 
Conversion option derivative liabilities642 3,960 
Long-term debt, net of unamortized debt issuance costs83,688 80,621 
Other non-current liabilities553 868 
Deferred income taxes liability78 108 
Total liabilities145,237 138,490 
Stockholders’ equity:
Common Stock, $0.0001 par value, authorized 500,000,000 shares; 74,548,216 shares issued and 72,955,088 shares outstanding at June 30, 2023 and 73,265,621 shares issued and outstanding at December 31, 2022
7 7 
Series A Convertible Preferred Stock, $0.0001 par value, authorized 10,000,000 shares; 165,045 shares issued and outstanding at June 30, 2023 and December 31, 2022
— — 
Additional paid-in capital195,586 186,250 
 Treasury Stock, 1,593,128 and 0 shares at June 30, 2023 and December 31, 2022
(894)— 
Accumulated deficit(109,977)(63,082)
Total stockholders’ equity84,722 123,175 
Total liabilities and stockholders’ equity$229,959 $261,665 



Consolidated Statements of Operations (Unaudited)
(in thousands except share data)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue
Patient services$53,426 $39,109 $103,699 $74,166 
Dispensary25,196 20,218 49,436 38,897 
Clinical trials & other1,602 1,594 3,281 3,019 
Total operating revenue80,224 60,921 156,416 116,082 
Operating expenses
Direct costs – patient services44,878 32,875 87,692 60,253 
Direct costs – dispensary20,111 16,754 39,256 32,078 
Direct costs – clinical trials & other118 150 252 287 
Goodwill impairment charges— — 16,867 — 
Selling, general and administrative expense28,726 28,348 57,556 58,154 
Depreciation and amortization1,329 1,098 2,598 2,085 
Total operating expenses95,162 79,225 204,221 152,857 
Loss from operations(14,938)(18,304)(47,805)(36,775)
Other non-operating expense (income)
Interest expense2,672 61 5,322 135 
Interest income(1,034)— (2,241)— 
Change in fair value of derivative warrant liabilities(118)(2,065)(261)(604)
Change in fair value of earnout liabilities(17)(10,800)(769)(50,240)
Change in fair value of conversion option derivative liabilities— — (3,318)— 
Gain on loan forgiveness— — — (183)
Other, net357 (15)214 136 
Total other non-operating income (loss)1,860 (12,819)(1,053)(50,756)
(Loss) income before provision for income taxes(16,798)(5,485)(46,752)13,981 
Income tax expense(99)32 (143)(148)
Net income (loss)$(16,897)$(5,453)$(46,895)$13,833 
Net income (loss) per share attributable to common stockholders:
Basic$(0.19)$(0.06)$(0.52)$0.15 
Diluted$(0.19)$(0.06)$(0.52)$0.15 
Weighted-average number of shares outstanding:
Basic74,119,91072,996,83673,786,37473,123,895
Diluted74,119,91072,996,83673,786,37476,106,201


Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Six Months Ended June 30,
20232022
Cash flows from operating activities:
Net (loss) income$(46,895)$13,833 
Adjustments to reconcile net (loss) income to cash and cash equivalents used in operating activities:
Depreciation and amortization2,598 2,085 
Amortization of debt issuance costs3,067 — 
Goodwill impairment charges16,867 — 
Share-based compensation9,072 15,067 
Change in fair value of liability classified warrants(261)(604)
Change in fair value of liability classified earnouts(769)(50,240)
Change in fair value of liability classified conversion option derivatives(3,318)— 
Realized loss on sale of investments11 — 
Unrealized loss on investments113 — 
Accretion of discount on investment securities(1,589)— 
Deferred taxes(30)131 
Gain on loan forgiveness— (183)
Credit losses(2)259 
Loss on disposal of property and equipment— 14 
Changes in operating assets and liabilities:
Accounts receivable(6,576)(9,200)
Inventories(2,907)(1,733)
Other receivables118 815 
Prepaid expenses1,091 1,152 
Operating lease right-of-use assets3,125 2,191 
Other assets(80)(86)
Accrued expenses and other current liabilities1,350 2,562 
Income taxes payable1 — 
Accounts payable3,751 (1,658)
Current and long-term operating lease liabilities(2,529)(1,767)
Other non-current liabilities(320)2 
Net cash and cash equivalents used in operating activities(24,112)(27,360)
Cash flows from investing activities:
Purchases of property and equipment(2,776)(2,344)
Cash paid for practice acquisitions(4,300)(8,920)
Purchases of marketable securities/investments(9,747)— 
Sales of marketable securities/investments60,127 — 
Net cash and cash equivalents provided by (used in) investing activities43,304 (11,264)
Cash flows from financing activities:
Payments made for financing of insurance payments(2,576)(2,481)
Payment of deferred consideration liability for acquisition(759)(759)
Principal payments on financing leases(81)(26)
Common stock repurchase from related party(894)(9,000)
Common stock issued for options exercised— 337 
Taxes for common stock net settled— (413)
Net cash, cash equivalents, and restricted cash used in financing activities(4,310)(12,342)
Net increase (decrease) in cash and cash equivalents14,882 (50,966)
Cash and cash equivalents at beginning of period14,010 115,174 
Cash and cash equivalents at end of period$28,892 $64,208 


Contacts
Media
The Oncology Institute, Inc.
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125

Revive
Michael Petrone
mpetrone@reviveagency.com
(615) 760-4542
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com

 EX-101.SCH 3 toi-20230808.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 toi-20230808_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 toi-20230808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Common Stock Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Redeemable Warrants Warrant [Member] Document Type Document Type Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Class of Stock [Axis] Class of Stock [Axis] Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 toi-20230808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0.jpg EX-99.1 begin 644 image_0.jpg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

DXGS M^BZ7,H*O@Y<2$OR$: UF^Q%'4$@FQ$_BZJ%OA%R,U!)WD =CY6ZH]=/?=5\J![L$1[ETX[5'7QU3G6#1RR4^ M57;+D'/QDV0THO^)_R55PF> 8QJ/GZC\@#P2LAE^)1)#3;DQI=;J#Q+;^$ O M#R73=8M&Z=U[*W%D,\$?V(BZ[3A^D47K\V;[;GQ+7!8:,@4$P*77ZK0]CL51 MF@K3^'(#AS:/C<8"3@QN(;/DO%:YJ2EH'JWT0D?Y@9F&/MT/QB$ MQJ.O,D#1\6'2L8##/#-DU X$5\U$V:"/Z74N>I87&#;MMLX;-#T^QY*00)TA MP85$V&.9Z;=H.R-^!XL6 Y\IUA"-/MN^9 <[9@R&0HE4I5:OFC5N^)I9 1!, M-7X!M>V_7 IUB(7=/OM\..2)A+VFJ1ZP Q2=QI0[GO.MZ#S+BPDZY39KC=JV MP*J)Q;X*\,75J"(AIVEFP##9&W(;@?+2&2[@L;CMC0:=MKG;>FWWLD%#DPA0-.(;KSLAE12T??%WGV4NE@B%PUZO=H_V;^]:L,?0 MR=I#K\C)@"U9UB#/,M/S32V+'2N3";FMS<=_+Y6@,L9P_<=O^I;G(E$W60L_ M7R'&5SEH&D\A@\0H#T!V'@\6;?,[%\-^!VQ+=U1*T9;&(Z_18%%X=K9;*M_S M' Z>856+@ IC0(]-JX[^2BK:/E196B,N4HBV2,7%TQW7A#7)[+,#JOTO8485 M&):R9XWC3:B3A J#LF7849OWZH2Q=CNDL4WT< I:>[;ZN M*-\A)W8)BAJM/<70*2UX%**"QH]VTS38F?2MS_\$-9_IJ/#8YJ3E.V0X])\/ MGG';J7=BL% MP%J6;Y_MK0$2F(P%J\N>4^U[INOB>]CFHBW*_2_X;'/[;Y8@NL9BO*;/GBM_?0[+9_]H>/LN[>KC\[U7E^U3 $"2)E95_3^V\I@ MCH&CIG2'@FA9,@.LR.^Q\)L3?X@MX-G.,_^2BXH[S[T+VK3W BY-U_CI'^*) M-77SA6I1L512.-ER?F5I%#M]%K(+\#B1J,#SEL !15()3G]H>O]UT,V.Q7&% MN%!:6KS0?U,WUJ0J>TY94F 8;0'* W(\;+O/:8R% M/:H].Y7[=MGF;UL NV5%\OT_3R4P]VA MLZ\$@X*WMPFR"^.-8(B@AK>O'1J6?B3%=-L"L"30ZYH^?4LAWEI_Z*7)MDNW MCKT)+=QY\J\,DW3H)J3B;=+R;?/]TJ6Q%A7 45)D&+OE=QK@0.-'_]:69(W.U3KML_V7=P#C=-\['"'LO2 M< -T@+:3?V)89G&TJ;8D7[[O.>-HRUSW31D9&',:U*F$7UZV"U#>],D;4QV7 MZ@^]HA 5#]6\SV"0Y^E#%JE.IVE9"')!L][4&E*X-/%#KD2(#!)"L!%QBG&% MXT9O4.\.C-ABE)A"4[0J;,]-S'\A5 FF;TD7KVY] V! M1VB=[0?5N#&=ID"Q'U@F^-$/6%*!M$6\5IFD$#J]US(#U5I;7JI&B!?X5Q;7 MO,OX<@=Q(>A18,K$A&F_6,YP*1SE%^3#%,S M:[HZ80@FL.NN?P.RBQ--T%4:CKQ"4S&:#JN.O [49>G.+8 LU!GV[_;<3/*\ M<:(=(*O:_R)8Y#'%9P#KK@O_ 1X"Q&P(8XA;>RZ7 9K;3O\#+-7=WFK#2)-, MDD^.H2F.<2Y-C-9\V'GZKW7[7@0S.%Q[G.;INSVR.M'_[KDH :( C&UIN!ZT M1OO)/X%;UG/A794H;U3^*<-1%)=J.?U7Z$L3=2>3R8"\_'DI<+#9?G!RIUN_ M4I7DMYW]*_??@2QH*O:N>^V^?%F#-13)&K7-!Q/^G?4OA,$5_--GL%_2FJ[@ M\LC&$:L;-!^TVD#E'H$&P&-6-Y_#H2#T2' <'QV+A]U)UDO@^?'&Y(!IP@H5*1+PW2I^!Q^,T3@8\-GE)48UX M6V1M&4-O&1QGRFI923Y8/286%/P(V]2 4ORSIO=?H]ET3^5^ ,3(]2,4BROH M3S:=!37<>>H=BDNW',-I"/JQ)@9?&TFUG_D[&-"9SLM3G168%2[&S!(9YI(7 MR$3;;?,C+'DO']Q3RY+CLE9O\ 8=X=@-C>F*5M^I7[FB-;4MV8!^"C9F$V1U M$TV@ZL -8C$Z&V] F&[5#=4"<220+3",-\.]..[V ^^LW?\\2\>'*D0UDNUW M:H[@5!:>'6NZ!+5M_^(]>!;S0W6UHKR^+]\;OGE$)=ZJ&V^E.<8PVHRI@.7/ M]U<9WP 9F%^%8T1 MMP'KM@FRAHEFL#-MG_X^@U/GZ>9/WX2F,-Q6$,! M4* MI_\)1'^ZIRK.4J/R]VL1LI_"LYOI4]25;&T[\R[%IF@6(:N0Y!,M2_5? M*@-5TE^YEV:H-!T%,R47;YWNN)Q(!!5EST%W]9BT'$\O#*AJ4LV<=(=3AM-<\#XZ=5%1$;4#6.C,(%VH"8L!1 MWI6EVK+G%**M0Y5[1J0?X:LAR[8[S=,LV,%COP7(*DN+!ZX?!O@JP0Z\_VHB MXDL ESWT*F@^\%$FZTZ,R3[1-)PEBXUFARKN6%>JR-([([;5/HNKBEBSJY,F M9P3RT:?#F)Q&R!?V7)."5$\@6MGWZ%D*6IPAD\_1#*M#%?T.9;]UH6EX3K M)7!9@*]M;EB)QF3''?F'_9?W*4O^M_S 2\&UY63")R]_1B8J=AL1LO/]2KA0 MVQ=_13IV_S-[;'DT9,F3SZPO>OR7-6;!"0/W?\:UALFLCP?9%IU-8 5PKL;A M%Q8]OB/[A,S5QA>%CEP__)V0S9 9RJ!L9MJOJA"O..@%*K;M\S]C1)(72/95BUYIO&C7UMF MVAGP43FJY=AO%.+BSB_^+B_?5@.=Y-COG,8IH>H>VT+;J;^#7:X1%U5+=G1= M*@5>D=F(RH&RZCG8:*5X3G[W&WI M_A>4[^^FP";P[/+<8/,G;V$=Q,7-'_W:.MU#8S 5JVB>[I7NW27=_Y)CZ0[: M&IYWF[3*(Z]*P=DX^.I Y7[YWEU#U)P15H_$'_TPR3 $M*D\@H M% W."LTD6#I"8:XE9O;1N$28(Q9<9;@T@_XB% A<%A7)74D0QLL&TFF$S19K)]GX5II7),FFTV/"5=P M+2;.,4D6\ZP8AHFQ;!SI/;Y'+29&6OA;G]TCY+$@"[G5FL;^:A#:!C!:V'-N-(?_U;ZRV@!H VS3%L*O1,+!8ZU2O#->A MS\- :"V_+E8<.51D,4R2(0;BQ+DW@"]\)<8Z*R-%GQ',IRT\2Q)"8(K"7=+ M!H;P5&&D!V&'?ANF#C(M9%X D%<:'YRPZD2V8FA8R,%D7@.IS'TW2]HCBYY[ M-;C9W$7XAZW<([NS]IVP4LG&9;(%")-7TEM20UY M3.+^UF?W"'DLR$(?BJ;HZ]-D;@+)]:Z:TOD3:6'T"[+8W3A^ MVN4C=-9P6:NK4!N;EZQ)M&E9R)(_9!,^<""S5 M. MAL%7,ZM*"OLKRMATE'1*05#G8;?E:%LX9ED+,"QMG>F1_R>_!M]\B^\:EY<^ MXW.9^,P3KNOT= 6U',N UPSL$-5Q#K+_37DLR I@!&[2/&L'WS\[X59M&+5[ M<,(T>4*HZC%# P>W.+*^D"LA_H/="AP2 MQ.4DNJO>#[NMX'J3N#[:3O'\,UU M?#9R^7]9A,Z:)1+_#]3G1RV/!5E! $2N2/PZ1F&0'I!W)^GF5@&(]]P7+DFS MD32U&DE,F%>O:1&O56K#=:U^9L6/N5(;80: (V ]$7%K&\\WO?^Z7+1=)LJ7 MENYJ/?NO.[7G JM6(,IQFNV8M_H2R.XUK9%D2FMW=ND=C0NVYGEK MA]$YX_0&*3); 1EWEJUFD*(+Z5-P4AJ\;]^RP>=8BH?=.&D17/QTJGW>>G?5 M#Y[RJFE*7KY-?F]*K:AHMON:L'8LT=HYR/ZTY'M EE@]7#1BT.JLP*QMG!"& MWIA&-^WT89H3&G-P+],L',7A3#>,&A%O]E%QUPU! DRR% *I1,.T&6!(0R&?"BN@T.1"W)+:Q0 M&RYK3/U&1Y@A2P&A$/^+A'(0AM\"V:ROM2$DO,0; M'J*7/'DC7!LG0ZUOF5 MB(P:%.,:R.+\NKW/^E=TN#KD8P\:Y^1')M\#LO!K<8H31R^MA:LG\1U@^)J:"0PF &&H4NMK[YHG75YO/$&FC)(% M&;)"ACXP0Q8'&DR^8+=QY9I6?T6KOZ$Q:%U^&E]>&^BM/(09L624"U=AE^2- MU9X$SPQ'4#;7)B<_+7D2R&):%4\6XR)KIH2325"-E[6ZRX \88HBAL#T\ TH M7=F4J7UQ^8[9I5[Q:%T^C7-MS.[I,3H T]?5NBO"*6KSK7GK:A3Q'7 :VS__ M,\Z_W7C;LD*4=Z?V-,5LGG>:DY^F/!ED,RR=\CJ-5#J!JSKB<#*]'(JVZNPD M=0:7J!=F@%7A]%KS99Q.@YJ8*&,AW5LG:.5*M:'^KEGG"Z;Q;28)W6VED,O@6+ M87EW+#%L]\APNMA2!=^[L<@UG$WR+IV_+]+YDU'=]K)9B<_.CE"2%+@E+ #"C[XNAMZ<#PT MT7"V[=,_S+1?77,87"T?7SO(9G =+F$-6@Y?'\7+(WA-\PR3'!3V6.S5' M%>4[ZXZ\-EAU8*;SJGFRPV72^%Q+?K?>Z]*M6F:L,WVS/36#-PXU?+1;ADO] M;R$T(%\FR5>)MH!FK3OPDK;M2B+B9G 5UR><&Y23'[<\!A6I2BOKB2OMB1?B0X63MX"R-:4 M;>LX^_?%X89D'&?MD6R$[,+3.9/WQR^>61IM"GJ,U.X[G.. .3DN^7I0Q9S MNW%Z$_CY/ 6?+)6*!T-NJ]LRY]!/.8W37MM"Q.>@4W$.US(G"Y7A##G<-A>7 MDYQ\0YXZ9+/)+F1I/APCVYCW(VSWY@"15!G XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
Aug. 08, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Aug. 08, 2023
Entity Registrant Name The Oncology Institute, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39248
Entity Tax Identification Number 84-3562323
Entity Address, Address Line One 18000 Studebaker Rd, Suite 800
Entity Address, City or Town Cerritos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90703
City Area Code 562
Local Phone Number 735-3226
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001799191
Amendment Flag false
Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol TOI
Security Exchange Name NASDAQ
Redeemable Warrants  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
Trading Symbol TOIIW
Security Exchange Name NASDAQ

XML 9 toi-20230808_htm.xml IDEA: XBRL DOCUMENT 0001799191 2023-08-08 2023-08-08 0001799191 us-gaap:CommonStockMember 2023-08-08 2023-08-08 0001799191 us-gaap:WarrantMember 2023-08-08 2023-08-08 0001799191 false 8-K 2023-08-08 The Oncology Institute, Inc. DE 001-39248 84-3562323 18000 Studebaker Rd, Suite 800 Cerritos CA 90703 562 735-3226 false false false false Common stock, par value $0.0001 TOI NASDAQ Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share TOIIW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " !BE A799!YDAD! #/ P $P M@ %K$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "U% " ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 23 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.deitaxonomy.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports toi-20230808.htm item991-q22023earningsrele.htm toi-20230808.xsd toi-20230808_def.xml toi-20230808_lab.xml toi-20230808_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "toi-20230808.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "toi-20230808_def.xml" ] }, "inline": { "local": [ "toi-20230808.htm" ] }, "labelLink": { "local": [ "toi-20230808_lab.xml" ] }, "presentationLink": { "local": [ "toi-20230808_pre.xml" ] }, "schema": { "local": [ "toi-20230808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 2, "nsprefix": "toi", "nsuri": "http://www.deitaxonomy.com/20230808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "toi-20230808.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.deitaxonomy.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "toi-20230808.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Redeemable Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001799191-23-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001799191-23-000029-xbrl.zip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